{"entity":{"id":"anthracycline-payloads","kind":"term","name":"Anthracycline payloads","aka":["PNU-159682","nemorubicin metabolite payloads","anthracycline antibody conjugates"],"tldr":"Antibodies can carry potent relatives of an established chemotherapy family called anthracyclines. Researchers are testing these payloads as another way to kill targeted cancer cells.","summary":"PNU-159682 is an anthracycline derivative used in experimental antibody conjugates. A primary study of a uPAR-directed PNU-159682 conjugate reported tumor suppression and changes in the immune environment in pancreatic cancer models. It is a distinct scaffold from camptothecin TOP1 payloads. An anthracycline label alone does not establish the dominant mechanism, resistance profile or clinical safety of each derivative.","asOf":"2026-11-08","links":[{"label":"uPAR-directed anthracycline conjugate in pancreatic cancer models (2025)","url":"https://doi.org/10.1126/sciadv.adq0513"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/anthracycline-payloads/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"}]}}